Clinical trial

Pharmacogenomic Study of Neoadjuvant Eribulin for HER2 Non-overexpressing Breast Cancer

NCT01669252

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2012-08-01

PhasePHASE2

Study timeline

Study start (unknown)2012-08-01Date precision: month

Registry last updated2017-11-06

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Cancerunresolved

Interventions

EribulinDRUG · verified · RxNorm: eribulin

Sponsors & collaborators

SOLTI Breast Cancer Research Grouplead sponsor

Eisai Inc.collaborator

Mapped research locations

MadridSpain4 BarcelonaSpain3 ValenciaSpain2 SevilleSpain2 CologneGermany1 LisbonPortugal1 VillejuifFrance1 PortoPortugal1 ZaragozaSpain1 CórdobaSpain1 CoimbraPortugal1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01669252 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.